# Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)

Study · id `cardio:ct-nct05469659` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05469659](<https://clinicaltrials.gov/study/NCT05469659>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05469659

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT05469659. Randomized; no masking; primary purpose treatment. Start 2021-09-22 (actual); primary completion 2025-10-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT05469659, source copy `cardio:ctgov-nct05469659-2022-07-22`, retrieved 2026-11-18)
- Started: 2021-09-22 (actual) (ClinicalTrials.gov record NCT05469659, source copy `cardio:ctgov-nct05469659-2022-07-22`, retrieved 2026-11-18)
- Primary completion: 2025-10-30 (anticipated) (ClinicalTrials.gov record NCT05469659, source copy `cardio:ctgov-nct05469659-2022-07-22`, retrieved 2026-11-18)
- Completion: 2026-10-30 (anticipated) (ClinicalTrials.gov record NCT05469659, source copy `cardio:ctgov-nct05469659-2022-07-22`, retrieved 2026-11-18)
- Countries: Japan (ClinicalTrials.gov record NCT05469659, source copy `cardio:ctgov-nct05469659-2022-07-22`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05469659-2022-07-22`, retrieved 2026-11-18)

## The registry's words

- Brief title: Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)
- Acronym: TRUTH-DKD
- Condition: T2DM (Type 2 Diabetes Mellitus)
- Condition: Metformin
- Condition: SGLT2-Inhibitors
- Intervention (Drug): Tofogliflozin
- Intervention (Drug): Metformin
- Lead sponsor: Shinshu University
- Lead sponsor class: OTHER
- Collaborator: Kowa Company, Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as a collaborator: Kowa Company, Ltd. (`cardio:org-kowa-company-ltd`)

## Provenance

Content hash: c45ff34f7f74f625e4690914cd9d02bc422573ff20b7cb23b8eac10be2fea270
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
